Literature DB >> 2715639

Mixed IgA-IgG aggregates as a model of immune complexes in IgA nephropathy.

F B Waldo1, A M Cochran.   

Abstract

Patients with IgA nephropathy have circulating immune complexes containing IgA, IgG, and C3. We have mixed human IgG and IgA1 and heated them to form mixed aggregate. On sucrose density gradients IgG aggregates were 11 to 19S whereas IgA aggregates were either 11S or greater than 19S. Mixed aggregates had both an 19 and 11 S peak. The isoelectric point of aggregates with only IgG was 7 to 9 and of only IgA 4.5 to 5.5. The isoelectric point of mixed aggregates decreased as the percent IgA increased. IgG aggregates mixed with normal human serum caused 30% C3 activation (20 min, 37 degrees C) whereas IgA aggregates causes no activation. There was a linear decrease in C3 activation as the percent IgA increased. Mixed aggregates that contained either radiolabeled IgG or IgA were mixed with normal human serum (1 h, 37 degrees C) and then solubilized, reduced, and separated by 10% SDS-PAGE. Heavy m.w. bands, consistent with covalent bonding of C3b and C3bi to Ig H chain were only seen in lanes with labeled IgG. This was confirmed by Western blot analysis. A human dimeric IgA1 myeloma protein with rheumatoid factor activity was also studied. It caused 15% alternative pathway C3 activation but did not fix C3 to its H chain. Binding of aggregates (+/- C3) to E was tested. Aggregates with IgG C3 bound but IgA (+/- C3) did not. Addition of greater than 10% IgA to an IgG-C3 aggregate inhibited E binding. We conclude that IgG in mixed aggregates is the site of C3 fixation. In contrast, IgA does not fix C3 but instead lowers the isoelectric point, increases the size and inhibits binding to E. These properties would inhibit clearance and promote mesangial deposition and local C activation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2715639

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  The structure and function of human IgA.

Authors:  M A Kerr
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

2.  Association of a protective monoclonal IgA with the O antigen of Salmonella enterica serovar Typhimurium impacts type 3 secretion and outer membrane integrity.

Authors:  Stephen J Forbes; Daniel Martinelli; Chyongere Hsieh; Jeffrey G Ault; Michael Marko; Carmen A Mannella; Nicholas J Mantis
Journal:  Infect Immun       Date:  2012-04-02       Impact factor: 3.441

3.  Systemic immune response after mucosal immunization in patients with IgA nephropathy.

Authors:  F B Waldo
Journal:  J Clin Immunol       Date:  1992-01       Impact factor: 8.317

4.  Location of glomerular immune deposits, not codeposition of immunoglobulin G, influences definitive renal outcomes in immunoglobulin A nephropathy.

Authors:  Anthony S Alvarado; Nicole K Andeen; Sergey Brodsky; Alice Hinton; Tibor Nadasdy; Charles E Alpers; Christopher Blosser; Behzad Najafian; Brad H Rovin
Journal:  Nephrol Dial Transplant       Date:  2018-07-01       Impact factor: 5.992

Review 5.  The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.

Authors:  Dana V Rizk; Nicolas Maillard; Bruce A Julian; Barbora Knoppova; Todd J Green; Jan Novak; Robert J Wyatt
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

Review 6.  Gingival crevicular fluid as a periodontal diagnostic indicator- II: Inflammatory mediators, host-response modifiers and chair side diagnostic aids.

Authors:  G Gupta
Journal:  J Med Life       Date:  2013-03-25

Review 7.  The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy.

Authors:  Barbora Knoppova; Colin Reily; Nicolas Maillard; Dana V Rizk; Zina Moldoveanu; Jiri Mestecky; Milan Raska; Matthew B Renfrow; Bruce A Julian; Jan Novak
Journal:  Front Immunol       Date:  2016-04-12       Impact factor: 7.561

8.  The Metalloproteinase ADAMTS5 Is Expressed by Interstitial Inflammatory Cells in IgA Nephropathy and Is Proteolytically Active on the Kidney Matrix.

Authors:  Scott Taylor; Molly Whitfield; Jonathan Barratt; Athanasios Didangelos
Journal:  J Immunol       Date:  2020-09-11       Impact factor: 5.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.